Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Mónica Cabrero, Lucia López-Corral, Isidro Jarque, Fátima de la Cruz-Vicente, Estefanía Pérez-López, David Valcárcel, Jaime Sanz, Ildefonso Espigado, Guillermo Ortí, Carmen Martín-Calvo, Javier de la Serna, Dolores Caballero
Curative potential of allogeneic transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (NHL) could be enhanced by the integration of Ofatumumab (OFA), a 2nd generation anti-CD20 moAb, due to an antitumor effect and a role over graft-versus-host disease (GVHD). In this phase II trial (NCT01613300), we investigated safety and effectiveness of OFA-based reduced intensity conditioning (RIC). High-risk B-cell NHL patients with chemorrefractory disease or post-autologous SCT relapse were eligible. OFA was added to a standard RIC regimen...
January 2, 2024: Bone Marrow Transplantation
#2
JOURNAL ARTICLE
Quality of life and financial toxicity of hematopoietic stem cell transplant recipients in COVID-19.
Natália Naome Oshiro, Luciana de Alcantara Nogueira, Yasmin Hiorrana Dos Santos, Paulo Ricardo Bittencourt Guimarães, Luciana Puchalski Kalinke
OBJECTIVE: to evaluate and correlate the quality of life and financial toxicity of adult patients undergoing hematopoietic stem cell transplantation during the COVID-19 pandemic. METHOD: observational, analytical study, carried out with 35 patients in a reference hospital for transplantation in Latin America. For data collection, the Functional Assessment Cancer Therapy Bone Marrow Transplantation and COmprehensive Score for Financial Toxicity questionnaires were used...
2023: Revista Latino-americana de Enfermagem
#3
JOURNAL ARTICLE
Selene Pury, Milagros López Orozco, Gabriela Pichichero, Laura V Sasia, Daniela Morell, María S Álvarez, Ana L Basquiera, María E Mas, Karina Salvucci
Wiskott-Aldrich syndrome (WAS) is an X-linked genetic disorder caused by mutations in the gene that encodes the Wiskott-Aldrich syndrome protein (WASp). Here, we report the clinical case of an 18-month-old boy diagnosed with Wiskott-Aldrich syndrome, who did not have an HLA-matched related or unrelated donor and was treated successfully with a hematopoietic stem cell transplant (HSCT) from a haploidentical family donor. Graft-versus-host disease (GvHD) prophylaxis included post-transplant cyclophosphamide (PT-Cy)...
July 27, 2023: Archivos Argentinos de Pediatría
#4
JOURNAL ARTICLE
Alberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, Blanca Rius-Sansalvador, Carmen Albo, Rebeca Bailen, Pere Barba, Ana Benzaquén, Javier Briones, Ana Carolina Caballero, António Campos, Ignacio Español, Christelle Ferra, Sebastián Garzón López, Pedro Antonio González Sierra, Luisa Maria Guerra, Rafael Hernani, Gloria Iacoboni, Ana Jiménez-Ubieto, Mi Kwon, Lucía López Corral, Oriana López-Godino, Maria Carmen Martinez Munoz, Nuria Martínez-Cibrián, Juan Montoro Gómez, Laura Pérez-Ortega, Guillermo Ortí, Valentín Ortiz-Maldonado, Maria-Jesús Pascual, María Perera, Antonio Perez, Juan Luis Reguera, Jose M Sanchez, Jaime Sanz, Anna Torrent, Lucrecia Yáñez, Rosario Varela, Izaksun Ceberio Echechipia, Dolores Caballero, Anna Sureda
Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL) after failure of second-line therapy despite the lack of direct comparisons with allogeneic hematopoietic cell transplantation (alloHCT)-based strategies. Using the Grupo Español de Trasplante y Terapia Celular (GETH-TC) registry, we selected patients with the following characteristics: CART or alloHCT performed between 2016 and 2021; ≥18 years old; ABCL diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse...
June 2023: Bone Marrow Transplantation
#5
Ahmet Burak Dirim, Erol Demir, Seda Safak, Nurana Garayeva, Ayse Serra Artan, Ozgur Akin Oto, Yasemin Ozluk, Savas Ozturk, Halil Yazici, Sevgi Kalayoglu Besisik, Aydin Turkmen
BACKGROUND: Passenger lymphocyte syndrome (PLS) causes immune-mediated hemolysis in solid and bone marrow transplant recipients. Donor-derived antibodies against the recipient erythrocyte drive the pathogenesis. It is a rare entity in kidney transplantation, and most of the cases are self-limited. CASE PRESENTATION: A 36-year-old woman presented with fatigue 13 days after living donor renal transplantation. The operation was uneventful, and she was discharged with normal graft functions on the 11th day of transplantation Findings were consistent with cold agglutinin disease at her admission...
December 12, 2022: Nefrología
#6
JOURNAL ARTICLE
Marco Alejandro Jiménez-Ochoa, María Margarita Contreras-Serratos, Martha Leticia González-Bautista, Constantino López-Macías, Anahí Torres-Fierro, Elizabeth Urbina-Escalante
BACKGROUND: Hematopoietic stem cell transplants (HSCT) can be performed regardless of the ABO group compatibility between donor and recipient. ABO incompatibility in HSCT is related to pure red cell aplasia (PRCA), or passenger lymphocyte syndrome. The impact of ABO incompatibility on graft-versus-host disease and transplant-related mortality is controversial due to the heterogeneity of procedures carried out in different transplant centers. OBJECTIVE: To determine the prevalence of ABO incompatibility and its complications in a hematopoietic stem transplant unit...
January 1, 2023: Revista Médica del Instituto Mexicano del Seguro Social
#7
JOURNAL ARTICLE
M Quintero de Charry, J R Tovar-Cuevas, H Leon, C E Ocampo
BACKGROUND: Pediatric hemato-oncological (HO) patients are highly susceptible to the occurrence of adverse events (AE), nevertheless few research has been done in this field. Our aim was to describe the incidence, type, severity and preventability of AE in these patients, including bone marrow transplant (BMT) patients, and to identify patient's risk factors for having an AE. METHODS: Retrospective cohort study. Children under 18yo hospitalized at the HO or BMT ward in 2016 were eligible for the study...
March 2022: Journal of Healthcare Quality Research
#8
JOURNAL ARTICLE
Gabriela Caicedo-Herrera, Estephania Candelo, Manuela Olaya, Paola Pérez, Diego Medina, Harry Pachajoa
INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is an exaggerated activation of the immune system which can be either primary (familial) or secondary. Familial hemophagocytic lymphohistiocytosis type 3 (FHL-3) is a severe immune disorder, caused by mutations in the UNC13D gene, which codes for a protein crucial to the cytotoxic function of lymphocytes. OBJECTIVE: To describe the diagnostic relevance of next-generation sequencing in the approach of a patient with suspected FHL and to demonstrate the effectiveness of bone marrow transplantation as the only curative measure...
April 2021: Andes pediatrica: revista Chilena de pediatría
#9
JOURNAL ARTICLE
Mauricio Sarmiento, Patricio Rojas, Nicolás Triantafilo, James Campbell, María José García, Mauricio Ocqueteau, Vicente Sandoval, Andrés Rojas, José Tomás Gazmuri, Gonzalo Guerrero, Maximiliano Vergara, Pablo Bertin, Pablo Ramírez, Verónica Jara, Catherine Gutiérrez, Katherine Soto, Silvana Arellano, Isabel Pizarro, Carla Lorca
BACKGROUND: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. AIM: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups...
January 2021: Revista Médica de Chile
#10
JOURNAL ARTICLE
K Y Cueto Sarmiento, J A Baquero Rey, A Andrade Miranda, S A Bruey, M L Makiya, L D Mazzuoccolo, P A Enz
BACKGROUND: Extracorporeal photopheresis (ECP) is an immunomodulatory therapy used to treat graft-vs-host disease (GVHD) in adults and children. Few studies have examined its use in children. OBJECTIVE: To describe demographic characteristics, clinical response, adverse effects, and outcomes in a series of pediatric patients with acute or chronic GVHD treated with ECP. MATERIAL AND METHODS: We included all pediatric patients with acute or chronic GVHD treated with ECP by the dermatology department of Hospital Italiano de Buenos Aires between January 2012 and December 2018...
May 18, 2021: Actas dermo-sifiliográficas
#11
MULTICENTER STUDY
Leyre Bento, Antonio Gutiérrez, Silvana Novelli, Juan Montoro, J L Piñana, Lucía López-Corral, Mónica Cabrero, Alejandro Martín-Sancho, Gonzalo Gutiérrez-García, Marcela Ortiz-Moscovich, Mariana Bastos-Oreiro, Nieves Dorado, Ariadna Pérez, Rafael Hernani, Christelle Ferrà, Rocío Parody, Irene García-Cadenas, Pilar Herrera, Guillermo Rodríguez, Nancy Rodríguez, Carmen Martín, Lucrecia Yáñez, Joud Zanabili, María Rosario Varela, Oriana López-Godino, Inmaculada Heras, Ignacio Español, Carmen Martínez, José Antonio Pérez-Simón, Carlos Solano, Anna Sureda, Jordi Sierra, Antonia Sampol, Dolores Caballero
We performed a retrospective multicenter study including 140 patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) from March 1995 to November 2018. Our objective was to analyze long term outcomes. Seventy-four percent had received a previous auto-SCT (ASCT) and the median number of lines pre-allo-SCT was 3 (range 1-9). Three year-event free survival (EFS) and overall survival (OS) were 38% and 44%, respectively...
August 2021: Bone Marrow Transplantation
#12
JOURNAL ARTICLE
K Y Cueto Sarmiento, J A Baquero Rey, A Andrade Miranda, S A Bruey, M L Makiya, L D Mazzuoccolo, P A Enz
BACKGROUND: Extracorporeal photopheresis (ECP) is an immunomodulatory therapy used to treat graft-vs-host disease (GVHD) in adults and children. Few studies have examined its use in children. OBJECTIVE: To describe demographic characteristics, clinical response, adverse effects, and outcomes in a series of pediatric patients with acute or chronic GVHD treated with ECP. MATERIAL AND METHODS: We included all pediatric patients with acute or chronic GVHD treated with ECP by the Dermatology Department of Hospital Italiano de Buenos Aires between January 2012 and December 2018...
February 20, 2021: Actas dermo-sifiliográficas
#13
JOURNAL ARTICLE
Juan Pablo Torres, María Eugenia Castro-Moraga, Paula Catalán, Verónica De La Maza, Alejandra Vergara, Romina Valenzuela, Lorena Tapia, Mauricio Olivares-Morales, Mauricio J Farfán, María Elena Santolaya
BACKGROUND: Children undergoing hematopoietic stem cell transplant (HSCT) can develop respiratory viral infections (RVI) during fever episodes. There are few data about clinical outcomes in RVI and compared to bacterial infections (BI) in this population. AIM: To determine clinical outcome of RVI, compared to BI in children with HSCT. METHODS: Prospective study, patients ≤ 18 years with cancer and HSCT admitted with fever at a National Bone Marrow Transplant Center (Hospital Calvo Mackenna), Chile, (April-2016 to May-2019)...
August 2020: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
#14
JOURNAL ARTICLE
Manuel Guerreiro, Dolores Planelles, Cristóbal Aguilar-Gallardo, José Ignacio Lorenzo, Juan Montoro, Jaime Sanz, Aitana Balaguer, Inés Gómez, Pilar Solves, Ariadna Pérez, Miguel Blanquer, Ildefonso Espigado, Carlos Solano, José Luis Piñana
There are many studies on the polymorphism of the HLA system in healthy donor populations, such as registries of unrelated bone marrow donors. Investigations on the characterization of the HLA complex in hematopoietic stem cell transplant (HSCT) patients, however, are scarce, at least in the Spanish population. This study presents a large-scale analysis of allelic diversity and HLA distribution at a high-resolution level in 2886 patients undergoing HSCT in Spanish Centres of the "Grupo Español de Trasplante Hematopoyético y Terapia Celular" during a period of 11 years...
December 28, 2020: HLA
#15
JOURNAL ARTICLE
José I Trucco, Mariano Berro, Ana Lisa Basquiera, Pablo García, Sebastián Yantorno, Silvina Palmer, Alejandro Requejo, Adriana Vitriú, Gonzalo Bentolila, María Marta Rivas, Gonzalo Ferini, Juan José García, Jorge Milone, German Stemmelin, Gregorio Jaimovich, Cecilia Foncuberta, Juliana Martínez Rolón, Gustavo D Kusminsky
We retrospectively analyzed 570 adult patients who received allogeneic stem cell transplantation for malignant diseases. The outcomes were compared according to donor type. Most of the patients (60%) were transplanted for acute leukemia. Median follow-up was 1.6 years. Haploidentical allogeneic stem cell transplantation was more frequently performed for acute myeloid leukemia and in late stages than any other donor type. Non-relapse mortality at 100 days and one year for unrelated and haploidentical donors were similar, 19%-29% vs...
2020: Medicina
#16
JOURNAL ARTICLE
Elisa Cordero, Walter Goycochea-Valdivia, Ana Mendez-Echevarria, Luis M Allende, Laia Alsina, Maria Bravo García-Morato, Juana Gil-Herrera, Carlota Gudiol, Oscar Len-Abad, Francisco López-Medrano, David Moreno-Pérez, Patricia Muñoz, Peter Olbrich, Silvia Sánchez-Ramón, Pere Soler-Palacín, Clara Aguilera Cros, Juan Ignacio Arostegui, Isabel Badell Serra, Javier Carbone, Jesús Fortún, Luis I Gonzalez-Granado, Eduardo López-Granados, José Manuel Lucena, Rocío Parody, Jan Ramakers, José R Regueiro, Jacques G Rivière, Cristina Roca-Oporto, Rebeca Rodríguez Pena, Juan Luis Santos-Pérez, Carlos Rodríguez-Gallego, Olaf Neth
Primary immunodeficiencies (PIDs) are rare, undiagnosed and potentially fatal diseases. Clinical manifestations of PID can be fatal or leave sequelae that worsen the quality of life of patients. Traditionally, the treatment of PIDs has been largely supportive, with the exception of bone marrow transplantation and, more recently, gene therapy. The discovering of new affected pathways, the development of new molecules and biologics, and the increasing understanding of the molecular basis of these disorders have created opportunities in PIDs therapy...
November 2020: Enfermedades infecciosas y microbiologia clinica
#17
MULTICENTER STUDY
S Bobillo, P Abrisqueta, B Sánchez-González, E Giné, S Romero, M Alcoceba, E González-Barca, S González de Villambrosía, J M Sancho, P Gómez, L Bento, J Montoro, S Montes, A López, F Bosch
Burkitt's monomorphic posttransplant lymphoproliferative disorder (B-PTLD) is an uncommon subtype of PTLD. Owing to the paucity of this complication, clinical characteristics and outcome has not been fully described. Clinical characteristics and outcomes of 20 patients diagnosed with B-PTLD from 10 transplant centers belonging to the GEL/TAMO group were reviewed. Median time from transplant to B-PTLD was 7.2 years. All the cases fulfill the morphologic and genetic criteria of B-PTLD, whereas Epstein-Barr virus (EBV) was detected in 70% of cases...
December 2018: Annals of Hematology
#18
JOURNAL ARTICLE
Juan-Manuel Sancho, Rafael Duarte, Laura Medina, Sergi Querol, Pedro Marín, Anna Sureda
BACKGROUND AND OBJECTIVE: Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. Plerixafor, a reversible inhibitor of the binding of stromal cell-derived factor 1 to its cognate receptor CXCR4, has demonstrated a higher capacity for the mobilization of peripheral blood stem cells in combination with granulocyte colony stimulating factor (G-CSF) compared with G-CSF alone...
September 2, 2016: Medicina Clínica
#19
MULTICENTER STUDY
Christelle Ferrà, Jaime Sanz, Miguel-Angel Díaz-Pérez, Mireia Morgades, Jorge Gayoso, José-Rafael Cabrera, Teresa Villaescusa, María-Antonia Sampol, Francesc Fernández-Avilés, Carlos Solano, Miguel Ortín, Rafael Duarte, Marian Cuesta, Inmaculada Heras, Javier de la Serna, José-María Moraleda, Cristina Barrenetxea, Marta González-Vicent, Guillermo Sanz, Josep-Maria Ribera
Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 10(9)/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 × 10(9)/L...
March 2015: Leukemia & Lymphoma
#20
MULTICENTER STUDY
R Hladun, I Badell, M González, A M Martínez, J Sánchez de Toledo, M T Olivé, M E González, I Elorza, C Díaz de Heredia
INTRODUCTION: Children with primary immunodeficiency have severe life-threatening infections and a higher prevalence of autoimmune problems, allergy and lymphoproliferative disorders. Allogenic hematopoietic stem cell transplantation has been the only potentially curative option. PATIENTS AND METHODS: Patients with primary immunodeficiency underwent allogenic stem cell transplantation in the period 1985-2011, and registered in the Spanish Working Party for Bone Marrow Transplantation in Children...
February 2015: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
